• HOME >
  • IBL News >
  • Novel Hypertension Medicine Based on an Antisense Oligonucleotide Targeting Angiotensinogen

IBL News

Product News

Product News2023/12/22
Novel Hypertension Medicine Based on an Antisense Oligonucleotide Targeting Angiotensinogen
Any IBL product introduced in this IBL news is applicable for research use only and it cannot be used for diagnosis or medical purpose.

Ionis Pharmaceuticals (USA) is developing a novel hypertension Medicine (IONIS-AGT-LRx) based on antisense oligonucleotide (ASO) targeting angiotensinogen (AGT) and shown to reduce blood AGT levels and significantly decrease both maximum and minimum blood pressure in Phase II trials with hypertension patients.

Please refer to the following publication for more details.
IONIS-AGT-LRx is a 20-mer ASO conjugated with three molecules of GalNAc and targeting the 3' untranslated region of human AGT mRNA. IONIS-AGT-LRx is incorporated into the hepatocyte by binding GalNAc to asialoglycoprotein receptors on the hepatocyte membrane. Then hybridizes to AGT mRNA, induces degradation of the mRNA by RNase H, and eventually suppresses AGT synthesis in a hepatocyte-specific manner. AGT synthesis in the kidney is hardly inhibited, so the drug does not cause side effects such as hyperkalemia and renal dysfunction.

In addition, renin-angiotensin system (RAS) inhibitors such as ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to cause “RAS escape” which angiotensin II increases by negative feedback, resulting decrease effectiveness of medicines. This ASO medicine targeting AGT, a precursor of angiotensin I and II, does not cause RAS escape and is effective for patients resistant to ACEIs and ARBs.

Apart from ASO drug, Alnylam Pharmaceuticals (USA) is also developing an antihypertensive drug that inhibits AGT synthesis by siRNA, and there are high expectations for the emergence of novel hypertension Medicines based on the so-called new modalities.

IBL offers wide range of ELISA kits to measure AGT.

<Total Angiotensinogen Assay kit>
#27412 Human Total Angiotensinogen Assay Kit - IBL
#27103 Mouse Total Angiotensinogen Assay Kit - IBL
#27104 Rat Total Angiotensinogen Assay Kit - IBL

<Intact Angiotensinogen Assay kit>
#27742 Human Intact Angiotensinogen Assay Kit - IBL
#27105 Mouse Intact Angiotensinogen Assay Kit - IBL
#27106 Rat Intact Angiotensinogen Assay Kit - IBL
Our AGT ELISA kits are well-established products and have been used in numerous studies and clinical trials, including measuring urinary AGT to monitor RAS activity in kidney.

Excessive activation of RAS causes hypertension but is also an accelerating factor for renal and cardiac diseases.

Hope our AGT-related products will be of great help in your RAS research.

Please feel free to contact us.

Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp

IBL Brand
IBL-Japan (Specific Antibody Development) 30sec video

IBL-Japan (Specific Antibody Development) 2min video

LipoSEARCH® - Lipoprotein Analyzing Systems (Patented GP-HPLC Systems) 30sec video